With new device innovations and clinical data now available, suprachoroidal delivery is emerging as a viable, patient-friendly alternative to intravitreal and subretinal injections.

• Understand why biopharma and gene therapy companies are now choosing suprachoroidal delivery to directly target the retina and choroid, overcome the limitations of intravitreal and subretinal injections, and reduce patient burden
• Learn how a tangential suprachoroidal delivery approach with the Everads Injector performed in a first-in-human trial, demonstrating safety, efficacy, and stable IOP with only topical anesthesia
• See how the Everads injector supports a rapid distribution of both small-molecule and gene therapy delivery to the back of the eye, and volumes up to 200µL tolerated in preclinical models
• Discover how the injector’s ease-of-use could support future adoption, with procedures completed in ~40 seconds, no accidental IVTs observed in clinical use, and simplified global training for retinal surgeons and CROs